Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
Recruitment status was Active, not recruiting
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known whether donor stem cell transplant is more effective with or without chemotherapy in treating primary myelodysplastic syndrome.
PURPOSE: This phase III trial is studying how well donor stem cell transplant given with chemotherapy works and compares it with donor stem cell transplant without chemotherapy in treating children with primary myelodysplastic syndrome.
Other: laboratory biomarker analysis
Procedure: allogeneic bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
|Study Design:||Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood|
- Patient numbers in the different FAB subtypes [ Designated as safety issue: No ]
- Survival [ Designated as safety issue: No ]
- Event-free survival [ Designated as safety issue: No ]
|Study Start Date:||July 1998|
- Determine, by a standard approach, the frequency of different FAB subtypes in children with primary myelodysplastic syndromes.
- Determine the frequency of cytogenetic and molecular abnormalities in these patients.
- Determine the survival of patients treated with allogeneic stem cell transplantation with or without induction chemotherapy.
- Determine the rate of complete remission in patients treated with these regimens.
- Determine the event-free survival of patients treated with these regimens.
- Determine the relapse rate, morbidity, and mortality of patients treated with these regimens.
- Determine different subsets of patients who benefit from these regimens.
OUTLINE: This is a multicenter study. Patients are stratified according to FAB subtype (refractory anemia (RA) or RA with ringed sideroblasts (RARS) vs RA with excess blasts (RAEB) vs RAEB in transformation (RAEB-t) vs juvenile myelomonocytic leukemia (JMML)).
Patients undergo complete medical and physical examination. Patients are screened for the following aberrations: -7, +8, +21, t(8;21), t(15;17), and inv(16). Smears of peripheral blood and bone marrow, as well as bone marrow biopsies and all cytogenetic and molecular studies performed on blood or bone marrow, are evaluated by a panel of international experts.
Patients with progressive RA or RARS undergo allogeneic stem cell transplantation (ASCT) according to EWOG-MDS SCT studies. Patients with stable RA or RARS wait for an optimal donor before undergoing ASCT. Patients with RAEB with fewer than 15% bone marrow blasts undergo ASCT. Patients with RAEB with at least 15% bone marrow blasts and patients with RAEB-t with fewer than 30% bone marrow blasts receive standard acute myeloid leukemia (AML) induction therapy and then undergo ASCT. Patients with RAEB-t with at least 30% bone marrow blasts are considered for standard AML induction therapy.
Patients with advanced JMML undergo evaluation for splenectomy and receive chemotherapy with mercaptopurine and cytarabine every 3-4 weeks (for 1-4 doses). Patients then undergo ASCT.
Patients are followed every 6 months.
PROJECTED ACCRUAL: Not specified
|Universitaetskinderklinik - Universitaetsklinikum Freiburg|
|Freiburg, Germany, D-79106|
|Study Chair:||Charlotte Niemeyer, MD||Universitaetskinderklinik - Universitaetsklinikum Freiburg|